The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

Progestin-only products may be a "safer alternative" for this patient population, according to a new analysis. 

Researchers examined data from nearly 31,000 adult patients hospitalized with COVID-19, sharing their findings in Circulation: Arrhythmia and Electrophysiology.

Erin D. Michos, MD, co-editor in chief of the American Journal of Preventive Cardiology, discusses gender differences in heart disease presentations.

Briefly trained in point-of-care cardiac ultrasound, 72% of second-year medical students obtained clinical-quality views from a mannequin and 61% made the correct diagnosis in a volunteer simulated patient.

CBD is generally viewed as a safe, well-tolerated treatment option, but there is still limited research on how it interacts with other medications commonly prescribed by cardiologists. 

The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.

A total of 37,073 MRI examinations conducted at 552 facilities across the U.S. between January 2010 and March 2020 were included in the analysis.